Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 10, 2021-30
eCollection

Optimal Management of Seizures Associated With Tuberous Sclerosis Complex: Current and Emerging Options

Affiliations
Review

Optimal Management of Seizures Associated With Tuberous Sclerosis Complex: Current and Emerging Options

Shelly Wang et al. Neuropsychiatr Dis Treat.

Abstract

Seizures are clinically significant manifestations associated with 79%-90% of patients with tuberous sclerosis complex. Often occurring within the first year of life in the form of infantile spasms, seizures interfere with neuropsychiatric, social, and cognitive development and carry significant individual and societal consequences. Prompt identification and treatment of seizures is an important focus in the overall management of tuberous sclerosis complex patients. Medical management, either after seizure onset or prophylactically in infants with electroencephalographic abnormalities, is considered first-line therapy. Vigabatrin and adrenocorticotropic hormone have emerged over the past few decades as mainstay pharmacologic modalities. Furthermore, emerging research on mammalian target of rapamycin inhibitors demonstrated promise for the management of seizures and subependymal giant cell astrocytoma. For appropriate surgical candidates with an epileptogenic zone associated with one or more glioneuronal hamartomas, ideally in noneloquent cortex, resective surgery can be considered, which provides a cure in 56% of patients. For medically refractory patients who do not meet criteria for curative surgery, palliative surgical approaches focused on reducing seizure burden, in the form of corpus callosotomy and vagus nerve stimulation, are alternative management options. Lastly, the ketogenic diet, a reemerging therapy based on the anticonvulsant effects of ketone bodies, can be utilized independently or in conjunction with other treatment modalities for the management of difficult-to-treat seizures.

Keywords: adrenocorticotropic hormone; epilepsy; ketogenic diet; mammalian target of rapamycin; vagus nerve stimulation; vigabatrin.

Similar articles

See all similar articles

Cited by 9 PubMed Central articles

See all "Cited by" articles

References

    1. National Institute of Neurological Disorders and Stroke . Tuberous sclerosis fact sheet. Bethesda, MD: National Institutes of Health; 2014. (NIH publication number 07-1846 2014 [webpage on the Internet]). [updated April 16, 2014]. Available from: http://www.ninds.nih.gov/disorders/tuberous_sclerosis/detail_tuberous_sclerosis.htm.
    1. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med. 2006;355(13):1345–1356. - PubMed
    1. Roach ES, Sparagana SP. Diagnosis of tuberous sclerosis complex. J Child Neurol. 2004;19(9):643–649. - PubMed
    1. Au KS, Williams AT, Roach ES, et al. Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States. Genet Med. 2007;9(2):88–100. - PubMed
    1. Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet. 2008;372(9639):657–668. - PubMed
Feedback